Rxivist logo

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

By Takuya Tada, Hao Zhou, Marie I Samanovic, Belinda M Dcosta, Amber Cornelius, Mark J Mulligan, Nathaniel R Landau

Posted 19 Jul 2021
bioRxiv DOI: 10.1101/2021.07.19.452771

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals were of low neutralizing titer (IC50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants.

Download data

  • Downloaded 37,111 times
  • Download rankings, all-time:
    • Site-wide: 197
    • In immunology: 8
  • Year to date:
    • Site-wide: 47
  • Since beginning of last month:
    • Site-wide: 660

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide